INT270775

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.09
First Reported 2007
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 0.64
Pain Relevance 0.03

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (DMD) extracellular space (PTH) extracellular region (PTH)
cytoskeleton (DMD) nucleus (DMD) cytoplasm (DMD)
PTH (Homo sapiens)
DMD (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 1 68.08 Quite High
headache 7 5.00 Very Low Very Low Very Low
Pain 4 5.00 Very Low Very Low Very Low
alcohol 4 5.00 Very Low Very Low Very Low
Potency 4 5.00 Very Low Very Low Very Low
backache 3 5.00 Very Low Very Low Very Low
cva 3 5.00 Very Low Very Low Very Low
Lasting pain 1 5.00 Very Low Very Low Very Low
depression 1 5.00 Very Low Very Low Very Low
anticonvulsant 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Osteoporosis 119 99.40 Very High Very High Very High
Congenital Anomalies 4 95.68 Very High Very High Very High
Aging 1 50.00 Quite Low
Breast Cancer 1 49.44 Quite Low
Endometriosis (extended) 7 40.12 Quite Low
Postmenopausal Osteoporosis 10 38.56 Quite Low
Hypercalcemia 35 5.00 Very Low Very Low Very Low
Kidney Stones 14 5.00 Very Low Very Low Very Low
Hip Fractures 13 5.00 Very Low Very Low Very Low
Vomiting 12 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The anabolic effect on BMD and fracture reduction, as well as adverse effects of the full-length PTH and of the truncated 1–34 N-terminal form (teriparatide) appears to be comparable (Hodsman et al 2003).
PTH Spec (appears) Regulation (effect) of BMD
1) Confidence 0.09 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2686344 Disease Relevance 0.30 Pain Relevance 0.03
Only interim analyses are available – one assessing calcium values during the first year of PTH, another evaluating BMD changes in subjects (27) treated with risedronate or alendronate for more than 6 months in the previous year.


PTH Regulation (changes) of BMD
2) Confidence 0.01 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2971708 Disease Relevance 0.34 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox